Setx as A Potential Therapeutic Target for Cancer, Neurodegenerative Diseases and Developmental Disorders

Target Name: SETX

NCBI ID: G23064

SETX

Setx as A Potential Therapeutic Target for Cancer, Neurodegenerative Diseases and Developmental Disorders

Setx (Sen1) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and muscle. It is a key regulator of cell division and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Recent studies have suggested that Setx may be a drug target (or biomarker) for a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders. This has led to increased interest in Setx as a potential therapeutic agent, with researchers studying its mechanisms of action and potential therapeutic applications.

One of the key mechanisms by which Setx is thought to contribute to the development and progression of cancer is its role in cell division. Setx is a transcription factor that is involved in the regulation of gene expression, and it has been shown to play a key role in the proliferation and survival of cancer cells.

In addition to its role in cell division, Setx has also been implicated in a number of other processes that are important for the development and progression of cancer. For example, Setx has been shown to promote the formation of cancer stem cells, which are cells that are capable of self-replication and have the ability to contribute to the development and progression of cancer.

Another potential mechanism by which Setx may contribute to the development and progression of neurodegenerative diseases is its role in the regulation of neural stem cells. Neural stem cells are a type of cell that are capable of self-replication and have the ability to contribute to the development and maintenance of neural tissue.

Setx has been shown to play a key role in the regulation of neural stem cells, and research has suggested that it may be involved in the development and progression of neurodegenerative diseases. For example, studies have shown that Setx is expressed in the brains of individuals with Alzheimer's disease, a neurodegenerative disease, and that its levels are decreased in the brains of individuals with neurodegenerative diseases.

In addition to its role in the regulation of neural stem cells, Setx has also been implicated in the development and progression of developmental disorders. For example, Setx has been shown to play a key role in the development and progression of Down syndrome, a genetic disorder that affects the development and growth of the brain.

In conclusion, Setx is a protein that is expressed in various tissues of the body and is involved in a number of processes that are important for the development and progression of cancer, neurodegenerative diseases, and developmental disorders. As such, Setx has generated significant interest as a potential therapeutic agent, with researchers studying its mechanisms of action and potential therapeutic applications. Further research is needed to fully understand the role of Setx in these processes and to develop effective treatments for the associated diseases.

Protein Name: Senataxin

Functions: Probable RNA/DNA helicase involved in diverse aspects of RNA metabolism and genomic integrity. Plays a role in transcription regulation by its ability to modulate RNA Polymerase II (Pol II) binding to chromatin and through its interaction with proteins involved in transcription (PubMed:19515850, PubMed:21700224). Contributes to the mRNA splicing efficiency and splice site selection (PubMed:19515850). Required for the resolution of R-loop RNA-DNA hybrid formation at G-rich pause sites located downstream of the poly(A) site, allowing XRN2 recruitment and XRN2-mediated degradation of the downstream cleaved RNA and hence efficient RNA polymerase II (RNAp II) transcription termination (PubMed:19515850, PubMed:21700224, PubMed:26700805). Required for the 3' transcriptional termination of PER1 and CRY2, thus playing an important role in the circadian rhythm regulation (By similarity). Involved in DNA double-strand breaks damage response generated by oxidative stress (PubMed:17562789). In association with RRP45, targets the RNA exosome complex to sites of transcription-induced DNA damage (PubMed:24105744). Plays a role in the development and maturation of germ cells: essential for male meiosis, acting at the interface of transcription and meiotic recombination, and in the process of gene silencing during meiotic sex chromosome inactivation (MSCI) (By similarity). May be involved in telomeric stability through the regulation of telomere repeat-containing RNA (TERRA) transcription (PubMed:21112256). Plays a role in neurite outgrowth in hippocampal cells through FGF8-activated signaling pathways. Inhibits retinoic acid-induced apoptosis (PubMed:21576111)

The "SETX Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SETX comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets